SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) NOVEMBER 17, 1997
Oncormed, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-13768 52-1842781
(State or other Jurisdiction (Commission File (IRS Employer
of Incorporation) Number) Identification No.)
205 Perry Parkway - Gaithersburg, Maryland 20877
(Address of principal executive offices) - (Zip code)
(301) 208-1888
(Registrant's telephone number, including area code)
(Former name of former address, if changed since last report)
<PAGE>
Item 5. Other Events
The Registrant hereby incorporates by reference the information contained in
Attachment A thereto in response to this Item 5.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Oncormed, Inc.
(Registrant)
Date: November 20. 1997 By:
L. Robert Johnston, Jr.
Vice President & CFO<PAGE>
NEWS RELEASE
For Further Information:
AT ONCORMED AT BURNS MCCLELLAN
Leslie Alexandre, Dr. P.H. Ruth Markowtiz (Investors)
Vice President, Corp. Affairs Liz Landy (Media)
(301) 208-1888, Ext. 521
ONCORMED FILES SUIT AGAINST MYRIAD GENETICS, INC. FOR INFRINGEMENT OF BRCA1
GENE SEQUENCE PATENT
Gaithersburg, MD -- November 17, 1997..Oncormed, Inc. (AMEX:ONM) today announced
that it has filed suit in U.S. District Court for the District of Columbia
against Myriad Genetics, Inc. The suit claims infringement of Oncormed's
recently issued BRCA1 gene patent (No. 5,654,155).
Oncormed (http://www.oncormed.com) develops and provides gene-based diagnostic
and information services for physicians, hospitals, clinical laboratories and
pharmaceutical companies. The Company's services include molecular profiling
and staging of tumors, laboratory confirmation of susceptibility to certain
cancers, and hereditary cancer risk assessment. Oncormed collaborates globally
with genomic, biotechnology and pharmaceutical companies to translate new
genetic discoveries into clinically-useful services.
###
